Lung Cancer Panel 1 EGFR ALK1: Comprehensive Genetic Testing for Targeted Lung Cancer Therapy
Understanding Lung Cancer Genetic Testing
The Lung Cancer Panel 1 EGFR ALK1 represents a breakthrough in precision oncology, offering comprehensive genetic analysis specifically designed for non-small cell lung cancer (NSCLC) patients. This advanced molecular diagnostic test examines critical genetic mutations that directly influence treatment response and clinical outcomes. By identifying specific alterations in the EGFR and ALK1 genes, healthcare providers can tailor treatment strategies to individual patient profiles, moving beyond traditional one-size-fits-all approaches to cancer care.
What This Test Measures and Detects
This sophisticated genetic panel utilizes two complementary methodologies to ensure comprehensive mutation detection:
FISH (Fluorescence In Situ Hybridization) Analysis
- Detects ALK1 gene rearrangements and fusions
- Identifies chromosomal abnormalities and translocations
- Provides visual confirmation of genetic alterations
Sanger Sequencing for EGFR Mutations
- Screens for activating mutations in exons 18-21 of the EGFR gene
- Identifies common mutations including L858R and exon 19 deletions
- Detects resistance mutations such as T790M
Who Should Consider This Test
This genetic panel is particularly beneficial for individuals experiencing:
Clinical Indications
- Newly diagnosed non-small cell lung cancer patients
- Patients with advanced or metastatic lung cancer
- Individuals with adenocarcinoma histology
- Never-smokers or light smokers with lung cancer
- Patients considering targeted therapy options
- Those who have failed initial chemotherapy treatments
Symptoms and Risk Factors
- Persistent cough or coughing up blood
- Shortness of breath or chest pain
- Unexplained weight loss and fatigue
- Family history of lung cancer
- Exposure to environmental carcinogens
Benefits of Genetic Testing for Lung Cancer
Personalized Treatment Selection
Genetic testing enables oncologists to select targeted therapies that specifically address the molecular drivers of your cancer, potentially leading to improved treatment efficacy and reduced side effects compared to conventional chemotherapy.
Improved Survival Outcomes
Patients with identified EGFR mutations or ALK rearrangements often experience significantly better response rates and progression-free survival when treated with appropriate targeted agents.
Informed Clinical Decision Making
Comprehensive genetic profiling provides valuable information for treatment sequencing, helping clinicians determine the most effective therapeutic strategy throughout the disease course.
Access to Clinical Trials
Specific genetic alterations may qualify patients for novel targeted therapy clinical trials, offering access to cutting-edge treatments not yet widely available.
Understanding Your Test Results
Positive Results
A positive result indicates the presence of targetable genetic mutations. Your oncologist will discuss appropriate targeted therapy options, such as EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, osimertinib) or ALK inhibitors (crizotinib, alectinib, lorlatinib).
Negative Results
A negative result means no targetable mutations were detected in the tested genes. Your healthcare team will explore alternative treatment strategies, including immunotherapy, chemotherapy, or additional genetic testing for other potential targets.
Inconclusive Results
In some cases, sample quality or technical factors may lead to inconclusive results. Your physician may recommend repeat testing or alternative diagnostic approaches.
Test Pricing and Details
| Test Component | Details |
|---|---|
| Test Name | Lung Cancer Panel 1 EGFR ALK1 |
| Regular Price | $600 USD |
| Discount Price | $450 USD |
| Turnaround Time | 5-7 days |
| Sample Type | Tumor tissue (paraffin embedded tissue blocks) |
| Testing Methods | FISH, Sanger Sequencing |
Pre-Test Instructions and Requirements
The Lung Cancer Panel 1 EGFR ALK1 requires a doctor’s prescription for testing. However, prescription requirements do not apply to patients undergoing surgery, pregnant individuals, or those planning international travel. Please consult with your healthcare provider to determine if this test is appropriate for your specific clinical situation.
Nationwide Testing Availability
We have diagnostic centers conveniently located across major metropolitan areas throughout the United States, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network ensures accessible genetic testing services for patients nationwide.
Take Control of Your Lung Cancer Treatment
Don’t leave your treatment decisions to chance. Comprehensive genetic testing can provide critical information to guide your lung cancer therapy. Our experienced genetic counselors and oncology specialists are available to discuss your testing options and help you understand how genetic information can impact your treatment journey.
Ready to Schedule Your Test?
Take the first step toward personalized lung cancer care. Contact our dedicated patient care team today to schedule your Lung Cancer Panel 1 EGFR ALK1 test or to learn more about how genetic testing can benefit your treatment plan.
Call or WhatsApp: +1(267) 388-9828
Our genetic testing specialists are available to answer your questions, assist with scheduling, and provide guidance on the testing process. Early genetic testing can make a significant difference in your treatment outcomes – don’t delay in obtaining this valuable information for your cancer care team.
